Utility and tolerability of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet (LP Nd:YAG) laser for treatment of symptomatic or disfiguring vascular malformations in children and adolescents - 12/08/17
Abstract |
Background |
Vascular malformations manifest with pain, bleeding, disability, and disfigurement in a subset of children. There are scant data available on the utility and tolerability of laser surgery for symptomatic or disfiguring non–port-wine stain vascular malformations in children.
Objective |
The objective of this study was to determine the utility and tolerability of the 1064-nm long-pulsed neodymium:yttrium-aluminum-garnet (LP Nd:YAG) laser for treatment of symptomatic or disfiguring vascular malformations in children.
Methods |
We conducted a retrospective review of 29 pediatric patients with non–port-wine stain vascular malformations who were treated with the LP Nd:YAG laser at our institution. We report patient characteristics, treatment parameters, outcomes, and complications.
Results |
Blinded assessment of clinical efficacy revealed good to excellent results in 66.7% of patients treated and poor to fair results in 25%. The overall rate of complications was 27%, with minor skin breakdown and blistering being the most common.
Limitations |
Our conclusions are limited by small sample size, pretreatment and posttreatment photographs in only a subset of patients, and lack of long-term follow-up.
Conclusion |
The LP Nd:YAG laser is a well-tolerated and effective treatment modality for a variety of non–port-wine stain vascular malformations in children.
Le texte complet de cet article est disponible en PDF.Key words : adolescent, angiokeratoma, childhood, circumscriptum, glomuvenous malformation, laser surgery, long-pulsed neodymium:yttrium-aluminum-garnet laser, pediatric, vascular malformation, venous malformation
Abbreviations used : GVM, LP Nd:YAG, PDL, PWS, VM, VVM
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 77 - N° 3
P. 473-479 - septembre 2017 Retour au numéro
Article précédent
- Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients
- Nausicaa Malissen, Laurence Vergely, Marguerite Simon, Agathe Roubertie, Marie-Claire Malinge, Didier Bessis
- Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis
- Huilin Tang, Wenting Wu, Shuangshuang Fu, Suodi Zhai, Yiqing Song, Jiali Han
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?